People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These oppositions challenge Gilead’s patent applications for the tablet formulation of the fixed-dose combination of sofosbuvir/velpatasvir and the polymorph form of velpatasvir.

Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018

Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional patents for routine improvements and derivatives. This brief provides technical information based Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

Intellectual Property rules stand amended

Source: The Hindu | July 02, 2018

Some powers with Customs revoked

The Union Ministry of Finance has amended Intellectual Property rules to revoke the power vested with Customs authorities to seize imported products based on complaints of patent infringement.

On June 22, the Ministry made two amendments to the Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007. Firstly, the Intellectual Property Rights (Imported Goods) Enforcement Amendment Rules, 2018, omits all reference to the Patents Act, 1970. Continue reading

Posted in IPR Enforcement, IPR policy, Patent infringement | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics

Volume 50, December 2016, Pages 193-223


Examine the intertemporal bounty (IB) system as an alternative to patents.
The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time.
Intertemporal bounties are funded by factor income taxes (labor & capital). The labor income tax is non-distortionary and the capital income tax is distortionary in the model.
Solve the dynamical system of the IB-regime economy when patents are replaced with bounty claims.
Evaluate the steady-state welfare effect and the intertemporal welfare effect, under labor income taxation and capital income taxation, respectively.

Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018

  • One in four Americans are unable to fill prescriptions due to high prices.
  • Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices.
  • Until the U.S. patent system is reformed, the pharmaceutical industry will continue to deny competition, block incentives discoveries and promote ineffective drugs.

Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

Patient Advocacy Successes in Fight for Medicines

by Fran Quigley, Health & Human Rights Journal | June 26, 2018

Access to essential medicines is a well-established component of the human right to health, but it is a right that remains elusive for millions of people across the globe. The United Nations estimates that 10 million people each year die because they cannot afford medicines. Even in the United States one out of every five Americans does not fill a prescription each year because they cannot afford it. Protected by monopoly patents, medicines are routinely priced at levels hundreds of times their manufacturing costs, and far exceeding research investments. The corporations that sell the medicines enjoy record-breaking profits yet still routinely raise prices by double-digit margins each year. Continue reading

Posted in Access to Medecines, Biologics/Biosimilars, Cancer, Hepatitis C, Uncategorized | Leave a comment

Transparency in drug pricing an important goal: Dutch health minister

By Rema Nagarajan, The Times of India | June 21, 2018

Netherlands health minister Bruno Bruins was in India recently to promote investments in life sciences and health with affordable healthcare being a key concern for both countries. Bruins spoke to the Times of India on the challenges of containing healthcare costs and how the Netherlands could contribute to achieving this.

Will the Netherlands support efforts to make pharma companies reveal how they calculate R&D costs on the basis of which they demand high prices?

Yes, we believe we should put pressure on companies to make their R&D costs transparent. This will allow us to have an informed debate on fair pricing and incentives for innovation. But we need to balance it with the fact that there could be new drugs for diseases and we might not get any new drugs if we push the companies too much. Continue reading

Posted in Drug prices, Uncategorized | Leave a comment